Long-term safety follow-up of GT005 gene therapy in age-related macular degeneration
Follows people with geographic atrophy from macular degeneration treated earlier with GT005 gene therapy.
Plain-language title generated from the registry record
Registry title: ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
Key facts
- Where
- Austin, Baltimore, Boston, Chesterfield, Cincinnati, Dallas, Durango, Eugene, Gainesville, Houston, Indianapolis, Lemont, New York, Philadelphia, Pompano Beach, Poway, Reno, Rochester, San Antonio, St. Petersburg, and West Des Moines, United StatesSee the 21 sites
- Phase
- Phase 2
Where in United States
- Retina Consultants of AustinAustin, United StatesNo longer taking part
- The Retina Care Center, Llc - Baltimore LocationBaltimore, United StatesNo longer taking part
- Ophthalmic Consultants of Boston (OCB)Boston, United StatesNo longer taking part
- Pepose Vision Institute, P.C - Midwest Vision Research FoundationChesterfield, United StatesNo longer taking part
- Cincinnati Eye InstituteCincinnati, United StatesNo longer taking part
- Texas Retina Associates (Tra) - Dallas MainDallas, United StatesNo longer taking part
- Southwest Retina Research CenterDurango, United StatesNo longer taking part
- Sterling Vision - Oregon Retina, LlpEugene, United StatesNo longer taking part
- Vitreo Retinal Associates Pa - the Millennium Center LocationGainesville, United StatesNo longer taking part
- Retina Consultants of Texas (Retina Consultants of Houston) - Texas Medical CenterHouston, United StatesNo longer taking part
- Midwest Eye Institute NorthsideIndianapolis, United StatesNo longer taking part
- University Retina and Macula Associates, P.C. - Lemont OfficeLemont, United StatesNo longer taking part
- Columbia University Medical CenterNew York, United StatesNo longer taking part
- Mid Atlantic Retina - Wills Eye HospitalPhiladelphia, United StatesNo longer taking part
- Rand Eye Institute, Inc. (Rei)Pompano Beach, United StatesNo longer taking part
- Retina Consultants San Diego - PowayPoway, United StatesNo longer taking part
- Sierra Eye AssociatesReno, United StatesNo longer taking part
- Retina Associates of Western New YorkRochester, United StatesNo longer taking part
- Retinal Consultants of San Antonio (Rcsa) - Medical CenterSan Antonio, United StatesNo longer taking part
- Retina Vitreous Associates of FloridaSt. Petersburg, United StatesNo longer taking part
- Wolfe Eye ClinicWest Des Moines, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gyroscope Therapeutics Limited
- Trial code
- NCT05481827EU 2024-510946-15-00
- Record updated
- 28 September 2026
- Original description
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.Read full original descriptionShow less
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
The purpose of this study is to evaluate the long-term safety of GT005 in participants with Geographic Atrophy (GA) secondary to AMD who have been treated in an antecedent study.
Inclusion: Able and willing to give written informed consent; Received GT005 in an antecedent study, GT005-01 (FOCUS, NCT03846193), GT005-02 (EXPLORE, NCT04437368) and GT005-03 (HORIZON, NCT04566445); Willing to attend study visits and complete the study procedures.